JPWO2022030606A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022030606A5 JPWO2022030606A5 JP2022518890A JP2022518890A JPWO2022030606A5 JP WO2022030606 A5 JPWO2022030606 A5 JP WO2022030606A5 JP 2022518890 A JP2022518890 A JP 2022518890A JP 2022518890 A JP2022518890 A JP 2022518890A JP WO2022030606 A5 JPWO2022030606 A5 JP WO2022030606A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- methyl group
- integer
- hydrogen atom
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- RHGAAELYAJWEML-UHFFFAOYSA-N 3-(13-methoxytridecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC(C)(CC1)C(CCCCCCCCCCCCCOC)=C(C)C1=O RHGAAELYAJWEML-UHFFFAOYSA-N 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- -1 -CH 2 OR 7 Chemical group 0.000 claims 2
- HNIYTHNWTUAYOQ-UHFFFAOYSA-N 3-(15-methoxypentadecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC(C)(CC1)C(CCCCCCCCCCCCCCCOC)=C(C)C1=O HNIYTHNWTUAYOQ-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- JSSVETUBIQAGJO-UHFFFAOYSA-N 2,4,4-trimethyl-3-(13-propan-2-yloxytridecyl)cyclohex-2-en-1-one Chemical compound CC(C)OCCCCCCCCCCCCCC(C(C)(C)CC1)=C(C)C1=O JSSVETUBIQAGJO-UHFFFAOYSA-N 0.000 claims 1
- PDOWBQNKOCAIMP-UHFFFAOYSA-N 2,4,4-trimethyl-3-(14-propan-2-yloxytetradecyl)cyclohex-2-en-1-one Chemical compound CC(C)OCCCCCCCCCCCCCCC(C(C)(C)CC1)=C(C)C1=O PDOWBQNKOCAIMP-UHFFFAOYSA-N 0.000 claims 1
- KRGNIBPBZAMLIM-UHFFFAOYSA-N 3-(12-ethoxydodecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CCOCCCCCCCCCCCCC(C(C)(C)CC1)=C(C)C1=O KRGNIBPBZAMLIM-UHFFFAOYSA-N 0.000 claims 1
- CRZVNKIQSYEEJY-UHFFFAOYSA-N 3-(12-methoxydodecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC(C)(CC1)C(CCCCCCCCCCCCOC)=C(C)C1=O CRZVNKIQSYEEJY-UHFFFAOYSA-N 0.000 claims 1
- IMSPTPAURUJGQK-UHFFFAOYSA-N 3-(13-ethoxytridecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CCOCCCCCCCCCCCCCC(C(C)(C)CC1)=C(C)C1=O IMSPTPAURUJGQK-UHFFFAOYSA-N 0.000 claims 1
- UGXWYMNFWRKHLK-UHFFFAOYSA-N 3-(14-ethoxytetradecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CCOCCCCCCCCCCCCCCC(C(C)(C)CC1)=C(C)C1=O UGXWYMNFWRKHLK-UHFFFAOYSA-N 0.000 claims 1
- BJLRPEFLWHKNLQ-UHFFFAOYSA-N 3-(14-methoxytetradecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC(C)(CC1)C(CCCCCCCCCCCCCCOC)=C(C)C1=O BJLRPEFLWHKNLQ-UHFFFAOYSA-N 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000014511 neuron projection development Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020135328 | 2020-08-07 | ||
| JP2020135328 | 2020-08-07 | ||
| PCT/JP2021/029246 WO2022030606A1 (ja) | 2020-08-07 | 2021-08-06 | 新規なシクロアルケノン化合物又はその塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022030606A1 JPWO2022030606A1 (https=) | 2022-02-10 |
| JPWO2022030606A5 true JPWO2022030606A5 (https=) | 2022-07-19 |
| JP7109705B2 JP7109705B2 (ja) | 2022-07-29 |
Family
ID=80118163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518890A Active JP7109705B2 (ja) | 2020-08-07 | 2021-08-06 | 新規なシクロアルケノン化合物又はその塩 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230295068A1 (https=) |
| EP (1) | EP4194435A4 (https=) |
| JP (1) | JP7109705B2 (https=) |
| KR (1) | KR20230043923A (https=) |
| CN (1) | CN116096361B (https=) |
| AU (1) | AU2021321705B2 (https=) |
| BR (1) | BR112023001832A2 (https=) |
| CA (1) | CA3188292A1 (https=) |
| MX (1) | MX2023001536A (https=) |
| TW (1) | TWI829001B (https=) |
| WO (1) | WO2022030606A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4477642A4 (en) * | 2022-02-09 | 2026-02-25 | Taiho Pharmaceutical Co Ltd | CRYSTALLINE FORM OF CYCLOHEXENONE COMPOUND |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6228893B1 (en) * | 1997-08-13 | 2001-05-08 | Meiji Milk Products Co., Ltd. | Cyclohexenone long-chain alcohol and medicament containing same |
| JP3836684B2 (ja) | 2001-02-19 | 2006-10-25 | 明治乳業株式会社 | 排尿障害治療剤 |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| ES2849425T3 (es) | 2016-01-22 | 2021-08-18 | Taiho Pharmaceutical Co Ltd | Método de fabricación de alcohol de cadena larga de ciclohexenona de alta pureza |
| TWI831738B (zh) * | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
-
2021
- 2021-08-06 KR KR1020237006213A patent/KR20230043923A/ko active Pending
- 2021-08-06 AU AU2021321705A patent/AU2021321705B2/en active Active
- 2021-08-06 WO PCT/JP2021/029246 patent/WO2022030606A1/ja not_active Ceased
- 2021-08-06 JP JP2022518890A patent/JP7109705B2/ja active Active
- 2021-08-06 US US18/040,862 patent/US20230295068A1/en active Pending
- 2021-08-06 TW TW110129168A patent/TWI829001B/zh active
- 2021-08-06 BR BR112023001832A patent/BR112023001832A2/pt unknown
- 2021-08-06 MX MX2023001536A patent/MX2023001536A/es unknown
- 2021-08-06 CA CA3188292A patent/CA3188292A1/en active Pending
- 2021-08-06 EP EP21853226.5A patent/EP4194435A4/en active Pending
- 2021-08-06 CN CN202180057124.1A patent/CN116096361B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (https=) | ||
| JP2013512277A5 (https=) | ||
| JPWO2020123827A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2010540508A5 (https=) | ||
| JP2013508279A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP2019504898A5 (https=) | ||
| RU2008127312A (ru) | Мезилатное пролекарство леводопы, его композиции и применение | |
| JPWO2022216971A5 (https=) | ||
| JP2011527333A5 (https=) | ||
| JP2010522710A5 (https=) | ||
| JP2009541224A5 (https=) | ||
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| JP2014505017A5 (https=) | ||
| JP2021513543A5 (https=) | ||
| ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| JP2015502371A5 (https=) | ||
| JP2010535706A5 (https=) | ||
| JPWO2022030606A5 (https=) | ||
| JP2009040767A5 (https=) | ||
| JP2011528662A5 (https=) | ||
| JP2019529501A5 (https=) | ||
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| JP2021532183A5 (https=) |